Sanofi taps se­r­i­al biotech in­vestor, en­tre­pre­neur as R&D chief — while pro­mot­ing busi­ness op­er­a­tions, dig­i­tal ...

Last year
People
Pharma

Scoop: Metageno­mi is prepar­ing for an IPO this fall, in what could jump­start a wave of pub­lic of­fer­ings

Last year
Financing
Startups

Can­cer drugs in US are ‘not af­ford­able,’ says Ger­man study, which sug­gests set­ting drug prices by in­di­ca­tion 

Last year
Pharma

In­cyte scores soc­cer star Mia Hamm as new spokesper­son to raise aware­ness of graft-ver­sus-host dis­ease

Last year
Pharma
Marketing

The cost of We­govy: $1.1M to pre­vent one ma­jor car­dio­vas­cu­lar event, Airfin­i­ty says

Last year
Pharma

Pfiz­er and BioN­Tech 'ready to ship' up­dat­ed Covid-19 vac­cine in EU on heels of CHMP rec­om­men­da­tion

Last year
Pharma
Coronavirus

Bot­u­lism risk: FDA de­liv­ers warn­ing let­ter to Gadal Labs for site mak­ing OTC pe­di­atric drugs 

Last year
FDA+
Manufacturing

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

Last year
Startups
Deals

Sens. Durbin and Grass­ley lever­age Medicare drug ne­go­ti­a­tion list to rein­vig­o­rate a push for drug prices in ads

Last year
Pharma
Marketing

De­mo­c­rat law­mak­ers call on FDA to take steps to pre­vent mis­use of Or­ange Book

Last year
Pharma
FDA+

FDA+ roundup: FDA is­sues fi­nal guid­ance on use of re­al-world ev­i­dence

Last year
R&D
Pharma

Here's how phar­ma com­pa­nies might re­move their prod­ucts from price ne­go­ti­a­tion

Last year
Law

FDA re­ject­ed Out­look Ther­a­peu­tic­s' Lu­cen­tis ri­val, and the com­pa­ny's stock plunged

Last year
Pharma
FDA+

CCM Bio­sciences breaks out of stealth with $25M; Two biotechs merge, to fo­cus on Parkin­son's

Last year
News Briefing

Af­ter de­lay, Abeona aims for fall FDA sub­mis­sion for rare skin con­di­tion cell ther­a­py

Last year
R&D
FDA+

Charles Riv­er Lab­o­ra­to­ries to lay off 55 em­ploy­ees in Cal­i­for­nia

Last year
People
Discovery

Hand­ful of biotechs ex­pect­ed to IPO this fall, but many are stuck in ‘hold­ing pat­tern’ un­til 2024

Last year
Financing

CEPI to in­vest up to $80M on ChA­dOx vac­cine plat­form, pre­vi­ous­ly used in As­traZeneca/Ox­ford Covid jab

Last year
Financing
Coronavirus

Up­dat­ed: No­vo Nordisk bags new obe­si­ty tar­get in lat­est biotech ac­qui­si­tion, inks R&D deal with spin­out

Last year
Deals

Epi­genic Ther­a­peu­tics en­ters crowd­ed glob­al gene ther­a­py mar­ket with $32M Se­ries A

Last year
Financing
Startups

PhI­II fail in Duchenne casts shad­ow over Fi­bro­Gen's top an­ti-fi­brot­ic pro­gram

Last year
R&D

Ex­clu­sive: 10x Ge­nomics CEO touts ‘in­cred­i­ble trac­tion’ with newest launch, ship­ping over 100 spa­tial bi­ol­o­gy ...

Last year
R&D

Eye drop pro­duc­er KC Phar­ma­ceu­ti­cals re­ceives FDA warn­ing let­ter

Last year
FDA+
Manufacturing

Bris­tol My­ers se­cures FDA la­bel ex­pan­sion for ane­mia drug Re­blozyl

Last year
Pharma
FDA+
First page Previous page 288289290291292293294 Next page Last page
A service from the Financial Times